PDCD1 and melanoma: To our knowledge this model is the first to show CRs of human tumor cells by autologous immune cells in a immune compromised mouse model—thus recapitulating the robust effects observed in some patients with malignant melanoma treated with immune therapy such as ACT or anti-PD1 antibodies.